IDH1 and glioblastoma: The overall survival (OS) was 55 months for the IDH-wt LGG patients and only 14.83 months for the IDH-wt GBM patients (Hazard ratio, 0.3213; 95% CI of hazard ratio, 0.2543-0.4060; P < 0.001).